- Conditions
- Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
- Interventions
- Intravitreal Aflibercept Injection
- Drug
- Lead sponsor
- Ophthalmic Consultants of Boston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic
- Interventions
- OPT-302, Lucentis™
- Drug
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- avacincaptad pegol, Sham
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more
- Conditions
- Non-exudative Age-related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Age - Related Macular Degeneration (AMD)
- Interventions
- Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 46 more
- Conditions
- Geographic Atrophy
- Interventions
- Lampalizumab, Sham
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
- Conditions
- Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
- Interventions
- Prescreening Assessments
- Diagnostic Test
- Lead sponsor
- Ascidian Therapeutics, Inc
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 8
- States / cities
- San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 5 more
- Conditions
- Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
- Drug
- Lead sponsor
- Nicole Fram M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- aflibercept, High-dose aflibercept
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more
- Conditions
- Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
- Interventions
- Netarsudil Ophthalmic
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stargardt Disease
- Interventions
- AAVB-039
- Biological
- Lead sponsor
- AAVantgarde Bio Srl
- Industry
- Eligibility
- 8 Years to 55 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Retinitis, Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 10 more
- Conditions
- Retinitis Pigmentosa, Choroideremia, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy from Age-related Macular Degeneration, X-lined Retinoschisis, Retinal Dystrophies
- Interventions
- Not listed
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Glaucoma, AMD, Diabetic Retinopathy (DR)
- Interventions
- Chronic Disease Intervention CDI
- Other
- Lead sponsor
- Interstat LLC
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- White Plains, New York
- Conditions
- Diabetes, Retinopathy
- Interventions
- Not listed
- Lead sponsor
- Scripps Whittier Diabetes Institute
- Other
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 1,229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Macular Degeneration
- Interventions
- Abicipar pegol
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Arcadia, California • Beverly Hills, California + 15 more
- Conditions
- Macular Edema
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more
- Conditions
- Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
- Interventions
- Faricimab Injection, sham treatment
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Low glycemic Mediterranean diet behavioral modification
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Retinitis Pigmentosa
- Interventions
- hRPC
- Drug
- Lead sponsor
- ReNeuron Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Boston, Massachusetts • Portland, Oregon
- Conditions
- Normal Healthy Subjects With No Known Ocular Diseases, Glaucomatous Eyes, Eyes With Retinal Diseases
- Interventions
- Maestro, iVue
- Device
- Lead sponsor
- Topcon Medical Systems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Pomona, California • New York, New York
- Conditions
- Exudative Age Related Macular Degeneration
- Interventions
- Ranibizumab, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, verteporfin
- Drug · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Wet Macular Degeneration
- Interventions
- BI 836880
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • New York, New York • Eugene, Oregon + 4 more
- Conditions
- Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
- Interventions
- Episcleral Dexamethasone
- Drug
- Lead sponsor
- Targeted Therapy Technologies, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California